Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.69 |
| ▸ | CDC42 | P60953 | 3/20 | 0.69 |
| ▸ | RAC1 | P63000 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449412 | 0.83 | PTGS2 (0.71) | PTGS2CDC42RAC1PTGS1PAK1 | |
| SCHEMBL10024799 | 0.83 | PTGS2 (0.71) | PTGS2CDC42RAC1PTGS1PAK1 | |
| SCHEMBL12286244 | 0.82 | PTGS2 (0.79) | PTGS2CDC42RAC1PTGS1PAK1 | |
| SCHEMBL2739340 | 0.82 | PTGS2 (0.66) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL23466702 | 0.82 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL14892 | 0.82 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| SCHEMBL13653083 | 0.82 | PTGS2 (0.69) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Ketorolac SCHEMBL4103 | 0.82 | PTGS2 (1.00) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Methane SCHEMBL29185931 | 0.82 | PTGS2 (0.69) | PTGS2CDC42RAC1PTGS1PAK1 | |
| Charcoal, Activated SCHEMBL30824313 | 0.82 | PTGS2 (0.69) | PTGS2CDC42RAC1PTGS1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023142996-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | 上海岸阔医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021259060-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京海融医药科技股份有限公司 | 2021-12-30 | — | — | WO | disclosed |
| EP-3242688-B1 | COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS | REILEY PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20160136089-A1 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION | EGALET US, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-8691869-B2 | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs | NICOX S.A. (FR) | 2014-04-08 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090042968-A1 | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLAC | ROXRO PHARMA, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-0821589-B1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NITROMED INC (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2009000723-A1 | PROCESS FOR PREPARING 1,4-BUTANDIOL MONONITRATE | NICOX S.A. (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-20080275010-A1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NITROMED, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1427392-B1 | NEW SELF EMULSIFYING DRUG DELIVERY SYSTEM | NICOX SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-20070112194-A1 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | NICOX S.A. (FR) | 2007-05-17 | — | — | US | disclosed |
| WO-2007012539-A2 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | NICOX S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4A11, CYP4F11 | PTGS2 403/4885CDC42 3972/4885RAC1 4687/4885 |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | PTGS2 12/4885CDC42 4615/4885RAC1 3860/4885 |
| US-20090042968-A1 | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLAC | KCNN3, KCNQ3, STING1 | PTGS2 1122/4885CDC42 4268/4885RAC1 3655/4885 |
| US-20080275010-A1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NOS2, NOS3, MB | PTGS2 6/4885CDC42 3848/4885RAC1 2014/4885 |
| US-20160136089-A1 | UNIT DOSE FORMULATIONS OF KETOROLAC FOR INTRANASAL ADMINISTRATION | ELAVL1, KCNQ3, LPXN | PTGS2 808/4885CDC42 2985/4885RAC1 3062/4885 |
| US-20070112194-A1 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | CYP2A13, CYP3A43, POR | PTGS2 1142/4885CDC42 4285/4885RAC1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.